Recent advances in therapeutic chalcones

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 12, 2004, Pages 1669-1691

  Ni, Liming ^a   Meng, Charles Q ^a   Sikorski, James A ^a  

^a AtheroGenics Inc   (United States)

Author keywords

, unsaturated ketone; 1,3 diphenyl 2 propen 1 one; Anti infective; Anti inflammatory; Antibacterial; Anticancer; Antimalarial; Antioxidant; Chalcone

Indexed keywords

3' BUTOXY 2,4 DIMETHOXYCHALCONE; 3,4 DIHYDROXY 2',5' DIMETHOXYCHALCONE; 3,4 HYDROXYCHALCONE DERIVATIVE; 3,4,5 TRIMETHOXY 4' FLUOROCHALCONE; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILEISHMANIAL AGENT; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIPARASITIC AGENT; AROMATASE INHIBITOR; BROUSSOCHALCONE A; BUTYLCRESOL; CHALCONE DERIVATIVE; DOXORUBICIN; ISOLIQUIRITIGENIN; LICOCHALCONE A; LICOCHALCONE B; LICOCHALCONE D; METHOTREXATE; NARINGENIN; PHLORETIN; QUERCETIN; SOFALCONE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHOHUMOL;

ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRITIS; BACTERIAL INFECTION; BREAST CANCER; CLINICAL TRIAL; CYTOTOXICITY; DISEASE MODEL; DIURESIS; DOSE RESPONSE; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; IC 50; LUNG NON SMALL CELL CANCER; NONHUMAN; OXIDATIVE STRESS; PAW EDEMA; PROSTATE CANCER; REVIEW; SEPTIC SHOCK; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

EID: 10344262032     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.12.1669     Document Type: Review

References (95)

1. SHIMOKORIYAMA M: Flavanones, Chalcones and Aurones. Geissman TA (Ed.) The MacMillan Company, New York, (1962):286-313.
2. SCHRÖDER J: The chalcone/stilbenesynthase type family of condensing enzymes. In: Comprehensive Natural Products Chemistry. Sankawa U (Ed.) (1999):749-771
3. BOWN D: Encyclopedia of Herbs and Their Uses. Folkard C (Ed.) Dorling Kindersley Publishing, Inc., New York, (1995):238,289,329,345.
4. AL-NAKIB W, HIGGINS PG, BARROW I: Intranasal chalcone, Ro-09-0410, as prophylaxis against rhinovirus infection in human volunteers. J. Antimicrob. Chemother. (1988) 20(6):887-892.
5. PHILLPOTTS RJ, HIGGINS PG, WILLMAN JS: Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers. J. Antimicrob. Chemother. (1984) 14(4):403-409.
6. CLUZAN RV, ALLIOT F, GHABBOUN S: Treament of secondary lymphedema of the upper limb with CYCLO 3 FORT. Lymphology (1996) 29(1):29-35.
7. BELTRAMINO R, PENENORY A, BUCETA A: An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic. Angiology (2000) 51(7):535-544.
8. WEINDORF N, SHULTZ-EHRENBURG U: Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatus and trimethylhesperidinchalcone. Z. Hautkr. (1987) 62(1):28-38.
9. DIMMOCK JR, ELIAS DW, KANDEPU NM: Bioactivities of chalcones. Curr. Med. Chem. (1999) 6(12):1125-1149.
10. OPLETALOVA V, SEDIVY D: Chalcones and their heterocyclic analogues as potential antifungal chemotherapeutics. Ces. Solv. Farm. (1999) 48(6):252-255.
11. OPLETALOVA V, RICICAROVA P, SEDIVY D, MELTROVA D, KRIVAKOVA J: Chalcones and their heterocyclic analogues as potential medicaments. Folia Pharm. Univ. Carol. (2000) 25:21-33.
12. OPLETALOVA V: Chalcones and their heterocyclic analogues as potential therapeutic agents for bacterial diseases. Ces. Solv. Farm. (2000) 49(6):278-284.
13. OPLETALOVA V, JAHODARL JD, OPLETAL L: Chalcones (1,3-diarylpropen-1-ones) and their analogues as potential therapeutic agents of diseases of the cardiovascular system. Ces. Solv. Farm. (2003) 52(1):12-19.
14. HARAGUCHI H, ISHIKAWA H, MIZUTANI K, TAMURA Y, KINOSHITA T: Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata. Bioorg. Med. Chem. (1998) 6(3 ):339-347.
15. CHENG ZJ, LIN CN, HWANG TL, TENG CM: Broussochalcone A, a potent antioxidant and effective suppressor of inducible nitric oxide synthase in lipopolysaccharide-activated macrophages. Biochem. Pharmacol. (2001) 16(8):939-946.
16. MIRANDA CL, STEVENS JF, IVANOV V et al.: Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. J. Agric. Food Chem. (2000) 48 9):3876-3884.
17. LEBEAU J, FURMAN C, BERNIER JL, DURIEZ P, TEISSIER E, COTELLE N: Antioxidant properties of di-tert-butylhydroxylated flavonoids. Free Radic. Biol. Med. (2000) 29(9):900-912.
18. VAYA J, BELINKY PA, AVIRAM M: Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Free Radic. Biol. Med. (1997) 23 2):302-313.
19. CIOFFI G, MORALES EL, BRACA A, DE TOMMASI N: Antioxidant chalcone glycosides and flavanones from Maclura (Chlorophora) tinctoria. J. Nat. Prod. (2003) 66(8):1061-1064.
20. WANG JP, TSAO LT, RAUNG SL, LIN CN: Investigation of the inhibitory effect of broussochalcone A on respiratory burst in neutrophils. Eur. J. Pharmacol. (1997) 320(2-3):201-208.
21. HSIEH HK, LEE TH, WANG JP, WANG JJ, LIN CN: Synthesis and anti-inflammatory effect of chalcones and related compounds. Pharm. Res. (1998) 15(1):39-46.
22. CALLISTE C-A, LE BAIL J-C, TROUILLAS P et al.: Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities. Anticancer Res. (2001) 21 3949-3956.
23. ZHAO F, NOZAWA H, DAIKONNYA A, KONDO K, KITANAKA S: Inhibitors of nitric oxide production from hops (Humulus lupulus L.). Biol. Pharm. Bull. (2003) 26(1):61-65.
24. ROJAS J, PAYA M, DEVESA I, DOMINGUEZ JN, FERRANDIZ ML: Therapeutic administration of 3,4,5-trimethoxy-4′-fluorochalcone, a selective inhibitor of iNOS expression, attenuates the development of adjuvant-induced arthritis in rats. Naunyn-Schmiedebergs Arch. Pharmacol. (2003) 368(3):225-233.
25. CHENG ZJ, LIN CN, HWANG TL, TENG CM: Broussochalcone A, a potent antioxidant and effective suppressor of inducible nitric oxide synthase in lipopolysaccharide-activated macrophages. Biochem. Pharmacol. (2001) 61(8):939-946.
26. HERENCIA F, FERRANDIZ ML, UBEDA A et al.: Novel anti-inflammatory chalcone derivatives inhibit the induction of nitric oxide synthase and cyclooxygenase-2 in mouse peritoneal macrophages. FEBS Lett. (1999) 453(1-2):129-134.
27. KO HH, TSAO LT, YU KL, LIU CT, WANG JP, LIN CN: Structure-activity relationship studies on chalcone derivatives. the potent inhibition of chemical mediators release. Bioorg. Med Chem. (2003) 11(1):105-111.
28. HERENCIA F, LOPEZ-GARCIA MP, UBEDA A: Nitric oxide-scavenging properties of some chalcone derivatives. Nitric Oxide (2002) 6 2):242-246.
29. HERENCIA F, FERRANDIZ ML, UBEDA A et al.: 4-Dimethylamino-3′,4′-dimethoxychalcone downregulates iNOS expression and exerts anti-inflammatory effects. Free Radic. Biol. Med. (2001) 30(1):43-50.
30. ROJAS J, DOMINGUEZ JN, CHARRIS JE, LOBO GM, PAYA M, FERRANDIZ ML: Synthesis and inhibitory activity of dimethylamino-chalcone derivatives on the induction of nitric oxide synthase. Eur. J. Med. Chem. (2002) 37(8):699-705.
31. ROJAS J, PAYA M, DOMINGUEZ JN, LUISA FM: The synthesis and effect of fluorinated chalcone derivatives on nitric oxide production. Bioorg. Med Chem. Lett. (2002) 12(15):1951-1954.
32. HERENCIA F, FERRANDIZ ML, UBEDA A et al.: Novel anti-inflammatory chalcone derivatives inhibit the induction of nitric oxide synthase and cyclooxygenase-2 (COX-2) in mouse peritoneal macrophages. FEBS Lett. (1999) 453(1-2):129-134.
33. HERENCIA F, FERRANDIZ ML, UBEDA A et al.: Synthesis and anti-inflammatory activity of chalcone derivatives. Bioorg. Med, Chem. Lett. (1998) 8(10):1169-1174.
34. HSIEH HK, TSAO LT, WANG JP, LIN CN: Synthesis and anti-inflammatory effect of chalcones. J. Pharm. Pharmacol. (2000) 52(2):163-171.
35. BARFOD L, KEMP K, HANSEN M, KHARAZMI A: Chalcones from Chinese liquorice inhibit proliferation of T cells and production of cytokines. Int. Immunopharmacol. (2002) 2(4):545-555.
36. DE LEON EJ, ALCARAZ MJ, DOMINGUEZ JN, CHARRIS J, TERENCIO MC: A new chloroquinolinyl chalcone derivative as inhibitor of inflammatory and immune response in mice and rats. J. Pharm. Pharmacol. (2003) 55(9):1313-1321.
37. DE LEON EJ, ALCARAZ MJ, DOMINGUEZ JN, CHARRIS J, TERENCIO MC: 1-(2,3,4-trimethoxyphenyl)-3-(3-(2-chloroquinolinyl))-2-propen-1-one, a chalcone derivative with analgesic, anti-inflammatory and immunomodulatory properties. Inflamm. Res. (2003) 52 6):246-257.
38. BALLESTEROS JF, SANZ MJ, UBEDA A et al.: Synthesis and pharmacological evaluation of 2′-hydroxychalcones and flavones as inhibitors of inflammatory mediators generation. J. Med. Chem. (1995) 38(14):2794-2797.
39. TANAKA S, SAKATA Y, MORIMOTO K et al.: Influence of natural and synthetic compounds on cell surface expression of cell adhesion molecules, ICAM-1 and VCAM-1. Planta Med. (2001) 67 2):108-113.
40. MADAN B, BATRA S, GHOSH B: 2′-hydroxychalcone inhibits nuclear factor-κB and blocks tumor necrosis factor-alpha- and lipopolysaccharide-induced adhesion of neutrophils to human umbilical vein endothelial cells. Mol. Pharmacol. (2000) 58(3 ):526-341.
41. HOWARD RB, MCDONALD AM, STEFANOPOULOS D et al.: The synthetic chalcone AGI-2048 inhibits several indices of diseases in rat adjuvant arthritis. FASEB J. (2003) 17(4):A666.
42. SUNDELL CL, LANDERS LK, QIU FH et al.: AGI-2048, a novel synthetic chalcone, inhibits eosinophilia, inflammatory gene expression and airway hyperresponsiveness in a murine asthma medel. Am. J. Respir. Crit. Care Med. (2003) 167:A357.
43. PETTIT GR, SINGH SB, HAMEL E, LIN CM, ALBERTS DS, GARCIA-KENDALL D: Isolation and structure of the strong cell growth and tubulin inhibtor combretastatin A-4. Experientia. (1989) 45 2):209-211.
44. LIN CM, SINGH SB, CHU PS et al.: Interaction of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol. (1988) 34(2):200-208.
45. MOLL UM, PETRENKO O: The MDM2-p53 interaction. Mol. Cancer Res. (2003) 1(14):1001-1008.
46. O'DWYER PJ, LACRETA F, NASH S et al.: Phase I study of thiotepa in combination with the glutathione trasferase inhibitor ethacrynic acid. Cancer Res. (1991) 51(22):6059-6065.
47. OAKLEY AJ, ROSSJOHN J, BELLO ML, CACCURI AM, FEDRICI G, PARKER MW: The three-dimensional structure of the human Pi class glutathion transferase P1-1 in complex with the inhibitor ethacrynic acid and its glutathione conjugate. Biochemistry (1996) 36 3):576-585.
48. PLOEMEN JH, BOGAARDS JJ, VELDINK GA, VAN OMMEN B, JANSEN DHM, VAN BLADEREN PJ: Isoenzyme selective irreversible inhibition of rat and human glutathione S-transferases by ethacrynic acid and two brominated derivatives. Biochem. Pharmacol. (1993) 45(3):633-639.
49. STOLL R, RENNER C, HANSEN S et al.: Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry (2001) 40(2):336-344.
50. KUMAR SK, HAGER E, PETTI C, GURULINGAPPA H, DAVIDON NE, KHAN SR: Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J. Med. Chem. (2003) 46 14):2813-2815.
51. REED JC: Apoptosis-based therapies. Nat. Rev. Drug Dis. (2002) 1:111-121.
52. ZHANG JY: Apoptosis-based anticancer drugs. Nature Rev. Drug Dis. (2002) 1:101-102.
53. RAFI MM, ROSEN RT, VASSIL A et al.: Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. (2000) 20:2653-2658.
54. Physician's Desk Reference. (1999):3425.
55. KELLOFF GJ, LUBET RA, RL et al.: Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomark. Prev. (1998) 7(1):65-78.
56. TAMIR S, EIZENBERG M, SOMJEN D, IZRAEL S, VAYA J: Estrogen-like activity of glabrene and other constituents ioslated from licorice root. J. Steroid Biochem. Mol. Biol. (2001) 78 291-298.
57. YAMAZAKI S, MORITA T, ENDO H et al.: Isoliqiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. Cancer Lett. (2002) 183:23-30.
58. BABA M, ASANO R, TAKAHASHI T et al.: Studio on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol. Pharm. Bull. (2002) 25 2):247-250.
59. BENSON AM, HUNKELER MJ, TALALAY P: Increase of NAD(P)H: quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc. Natl. Acad. Sci. USA (1980) 77(9):5216-5220.
60. MIRANDA CL, APONSO GL, STEVENS JF, DEINZER ML, BUHLER DR: Prenylated chalcones and flavanones as inducers of quinone reductase in mouse Hepa 1c1c7 cells. Cancer Lett. (2000) 149:21-29.
61. DINKOVA-KOSTOVA AT, MASSIAH MA, BOZAK RE, HICKS RJ, TALALAY P: Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl. Acad. Sci. USA (2001) 98 6):3404-3409.
62. HENDERSON MC, MIRANDA CL, STEVENS JF, DEINZER ML, BUHLER DR: In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica (2000) 30(3 ):235-251.
63. BRIDGES AJ: Chemical inhibitors of protein kinases. Chem. Rev. (2001) 101(8):2541-2571.
64. YANG EB, GUO YJ, ZHANG K, CHEN YZ, MACK P: Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives. Biochim. Biophys. Acta (2001) 1550:144-152.
65. NAKAMURA C, KAWASAKI N, MIYATAKA H et al.: Synthesis and biological activities of fluorinated chalcone derivatives. Bioorg. Med. Chem. (2002) 10:699-706.
66. SODERSTROM T, WADELIUS M, ANDERSSON SO et al.: 5α-Reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics (2002) 12(4):307-312.
67. STEERS WD: 5α-Reductase activity in the prostate. Urology 2001) 58(6.Suppl.1):17-24.
68. SHIMIZU K, KONDO R, SAKAI K, BUABARN S, DILOKKUNANANT U: A geranylated chalcone with 5α-reductase inhibitory properties from Artocarpus incisus. Phytochemistry (2000) 54:737-739.
69. DUCKI S, FORREST R, HADFIELD J et al.: Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. (1998) 8:1051-1056.
70. ROSS SA, ZAGLOUL A, NIMOF A, MEHMEDIC Z, SOHLY EN: A cytotoxic chalcone from Faramea salicifolia. Planta Med. (1999) 65(2):194.
71. DIMMOCK JR, JHA A, ZELLO GA et al.: Cytotoxic 4′-aminochalcones and related compounds. Pharmazie (2003) 58 4):227-232.
72. DIMMOCK JR, PERJESI P: Synthesis and antitumor activities of some cyclic chalcones. Gyogyszereszet (2001) 45(4):210-215.
73. HARAGUCHI H, TANIMOTO K, TAMURA Y, MIZUTAN K, KINOSHITA T: Mode of antibacterial action of retrochalcones from Glycyrrhiza inflata. Phytochemistry (1998) 48(1):125-129.
74. KABIR AM, SHIMIZU K, AIBA Y. IGARASHI M, TAKAGI A, KOGA Y: The effect of sofalcone on indomethacin-induced gastric ulcers in a Helicobacter pylori-infected gnotobiotic murine model. Aliment Pharmacol. Ther. (2000) (Suppl.1):223-229.
75. FRIIS-MØLLER A, CHEN M, FUURSTED K, CHRISTENSEN SB, KHARAZMI A: In vitro antimycobacterial and antilegionella activity of licochalcone A from Chinese licorice roots. Planta Med. (2002) 68(5):416-419.
76. ZHAI L, CHEN M, BLOM J, THEANDER TG, CHRISTENSEN SB, KHARAZMI A: The anitleishmanial activity of novel oxygenated chalcones and their mechanism of action. J. Antimicro. Chemother. (1999) 43 793-803.
77. KAYSER O, KIDERLEN AF: In vitro Leishmanicidal activity of naturally occurring chalcones. Phytother. Res. (2001) 15 148-152.
78. NIELSEN SF, CHRISTENSEN SB, CRUCIANI G, KHARAZMI A, LILJEFORS T: Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. J. Med. Chem. (1998) 41(24):4819-4832.
79. LIU M, WILAIRAT P, GO M-L: Antimalarial alkoxylated and hydroxylated chalcones: structural-activity relationship analysis. J. Med. Chem. (2001) 44(25):4443-4452.
80. LIN Y-M, ZHOU Y, FLAVIN MT, ZHOU L-M, NIE W, CHEN F-C: Chalcones and flavonoids as anti-tuberculosis agents. Bioorg. Med Chem. (2002) 10:2795-2802.
81. ELSOHLY HN, JOSHI AS, NIMROD AC, WALKER LA, CLARK AM: Antifungal chalcones from Maclura tinctoria. Planta Med. (2001) 67:87-89.
82. CHEN M, ZHAI L, CHRISTENSEN SB, THEANDER TG, KHARAZMI A: Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob. Agents Chemother. (2001) 45(7):2023-2029.
83. VIANA GS, BANDEIRA MA, MATOS FJ: Analgesic and anti-inflammatory effects of chalcones isolated from Myracrodruon urundeuva allemao. Phytomedicine (2003) 10(2-3):189-195.
84. LIN CN, LEE TH, HSU MF, WANG JP, KO FN, TENG CM: 2′,5′-Dihydroxychalcone as a potent chemical mediator and cyclooxygenase inhibitor. J. Pharm. Pharmacol. (1997) 49 5):530-536.
85. LIN CN, LU CM, LIN HC et al.: Novel antiplatelet constituents from formosan moraceous plants. J. Nat. Prod. (1996) 59(9):834-838.
86. ZWAAGSTRA ME, TIMMERMAN H, TAMURA M et al.: Synthesis and structure-activity relationships of carboxylated chalcones: a novel series of CysLT1 (LTD4) receptor antagonists. J. Med. Chem. (1997) 40(7):1075-1089.
87. 2 production by 2′-hydoxychalcone derivatives and the mechanism of action. J. Pharm. Pharmacol. (2001) 53 9):1295-1302.
88. LEE YN, YEH HI, TIAN TY, LU WW, KO YS, TSAI CH: 2′,5′-Dihydroxychalcone down-regulates endothelial connexin 43 gap junctions and affects MAP kinase activation. Toxicology (2002) 179(1-2):51-60.
89. MATSUURA M, KIMURA Y, NAKATA K, BABA K, OKUDA H: Artery relaxation by chalcones isolated from the roots of Angelica keiskei. Planta Med. (2001) 76(3):230-235.
90. AIDA K, TAWATA M, SHINDO H et al.: Isoliquiritigenin: a new aldose reductase inhibitor from Glycyrrhizae radix. Planta Med. (1990) 56(3):254-258.
91. LIM SS, JUNG SH, JI J, SHIN KH, KEUM SR: Inhibitory effects of 2′-hydroxychalcones on rat lens aldose reductase and rat platelet aggregation. Chem. Pharm. Bull. (2000) 48(11 ):1786-1789.
92. TAWATA M, AIDA K, NOGUCHI T et al.: Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. Eur. J. Pharmacol (1992) 212(1):87-92.
93. MENG CQ, ZHENG XS, NI L et al.: Discovery of novel heteroaryl-substituted chalcones as inhibitors of TNF-α-induced VCAM-1 expression. Bioorg. Med. Chem. Lett. (2004) 14:1513-1517.
94. MIDDLETON E, KANDASWAMI C, THEOHARIDES TC: The effects of plant flavonoids on mammalian cells: implication for inflammation, heart desease, and cancer. Pharmacol. Rev. (2000) 52(4):673-751.
95. O'NEILL PM, POSNER GH: A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. (2004) 47 12):2945-2964.